Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Breast Cancer Research

Figure 4

From: A clinically relevant gene signature in triple negative and basal-like breast cancer

Figure 4

Prognostic value of the combined B-Cell/IL-8 metagenes among TNBC. Kaplan Meier analysis of event free survival of 297 TNBC patients with follow up from the finding cohort A. Samples were stratified according to prognostic predictor of the combined B-Cell/IL-8 metagenes. "Good" refers to 95 samples with both high B-Cell and low IL-8 metagene expression whereas all other samples (n = 202) are referred as "Poor". A) Prognostic value of the B-Cell/IL8-metagene prognostic predictor in the 30 TNBC patients with follow up from the validation cohort-B. Samples were stratified as in (A). B) Prognostic value of the B-Cell/IL8-metagene prognostic predictor in the 75 TNBC patients with follow-up from the independent validation cohort-C. Samples were stratified as in (A). C) Prognostic value of the combined B-Cell/IL-8 metagenes among the subset of high grade (G3) TNBC tumors from all three cohorts -A, -B, and -C (n = 186). Samples were stratified as in (A). (Results from the individual cohorts are given in Additional file 1, Supplemental Figure S8). D) Prognostic value of the combined B-Cell/IL-8 metagenes among the subset of low to medium grade (G1 and G2) TNBC tumors from all three cohorts -A, -B, and -C (n = 77). Samples were stratified as in (A). (Results from the individual cohorts are given in Additional file 1, Supplemental Figure S8).

Back to article page